Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2026 10:00 ET | Source: Eascra Biotech

Eascra Biotech Takes First Place at TechConnect Bio in Space Innovation Challenge

Eascra Biotech, a nanomedicine startup, has won first place at the TechConnect Bio in Space Innovation Challenge
March 06, 2026 17:01 ET | Source: Faruqi & Faruqi LLP

NKTR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or...
March 05, 2026 09:00 ET | Source: Vera Therapeutics

Vera Therapeutics Appoints Christopher Hite to Board of Directors

Vera Therapeutics Appoints Christopher Hite to Board of Directors
February 24, 2026 09:00 ET | Source: Human Continuum Inc.

Human Continuum Appoints Dr. Michael Milligan, MD, MBA, as its Chief Medical Officer to Oversee Innovative Applications for Next-Generation Extracellular Vesicle Therapeutics

New York, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”), a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced...
February 19, 2026 03:30 ET | Source: Custom Market Insights

Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Global ALS therapeutics market is expected to grow from USD 1.05B in 2025 to USD 1.96B by 2034 at 11.5% CAGR, driven by new therapies and rising worldwide.
February 16, 2026 10:00 ET | Source: MarketsandMarkets Research Pvt. Ltd.

Global Oligonucleotide Therapeutics Market Set to Surge to USD 17.70 Billion by 2030 | MarketsandMarkets™

Delray Beach, FL, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Strategic investments in ASO and siRNA platforms, coupled with breakthrough delivery technologies, position oligonucleotide therapeutics as...
February 10, 2026 07:00 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide

Kailera and Hengrui report positive topline data from Hengrui’s Phase 2 clinical trial of oral ribupatide, a GLP-1/GIP receptor dual agonist peptide.
January 30, 2026 08:00 ET | Source: Alps Group Inc

Alps Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome Therapy

KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated...
January 22, 2026 09:00 ET | Source: Human Continuum Inc.

Human Continuum Appoints Dr. Omar Khalid Sial, Ph.D., as its Chief Scientific Officer to Spearhead the Development of Innovative Extracellular Vesicle Topical Formulations and Advanced Biologic Therapies

New York, N.Y., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”), a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced...
January 22, 2026 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair

CARMEL, Ind., Jan. 22, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel...